Beta-glucogallin

Beta-Glucogallin: A Comprehensive Reference

1. Identity: Chemical Names, Structure, and Classification

Beta-glucogallin (abbreviated BGG) is a naturally occurring plant polyphenolic compound belonging to the class of phenolic esters. It is chemically designated as 1-O-galloyl-β-d-glucopyranose and is a plant-derived polyphenolic ester regarded as the primary metabolite in the biosynthesis of hydrolyzable tannins. Glucogallin is a chemical compound formed from gallic acid and β-d-glucose. Its molecular formula is C₁₃H₁₆O₁₀, and it is registered under CAS number 13405-60-2. It is also known by the name 1-O-Galloyl-beta-d-glucose and is catalogued in PubChem under CID 124021.

Structurally, beta-glucogallin consists of a β-d-glucopyranose sugar core esterified at the 1-O position with gallic acid (3,4,5-trihydroxybenzoic acid). Evidence from nuclear magnetic resonance spectroscopy indicates that the compound is 1-(3,4,5-trihydroxybenzoate) 7-O-β-d-glucopyranoside. Chemically known as 1-O-galloyl-β-d-glucopyranose, it is a plant-derived polyphenolic ester and an intermediate metabolite formed in the pathway of penta-O-galloyl-glucose (β-PGG) synthesis.

Beta-glucogallin is classified under the broader category of galloylglucoses (simple gallotannins), which are hydrolyzable tannin precursors. It is distinct from beta-glucans, which are polysaccharides of an entirely different chemical class and origin.

2. Natural Sources and Botanical Distribution

Beta-glucogallin is widely distributed across the plant kingdom, with particularly high concentrations in certain fruits and trees. The natural sources of this compound include amla (Indian gooseberry), pomegranate, raspberry, mango, and Chinese white olive. It can also be found in oak species such as the North American white oak (Quercus alba), European red oak (Quercus robur), and the amla fruit (Phyllanthus emblica).

Beta-glucogallin is majorly found in amla, pomegranate, and strawberry. Within strawberry and raspberry fruits specifically, research has documented its biosynthetic origin: five glycosyltransferases (GTs) from two genera of the Rosaceae family (Fragaria and Rubus; including F.×ananassa FaGT2*, FaGT2, FaGT5, F. vesca FvGT2, and R. idaeus RiGT2) have been shown to catalyze the formation of 1-O-galloyl-β-d-glucopyranose (β-glucogallin), the precursor of ellagitannin biosynthesis. Green immature strawberry fruits were identified as the main source of gallic acid, β-glucogallin, and ellagic acid in accordance with the highest GT2 gene expression levels.

Cherry fruit (Muntingia calabura L.) also contains β-glucogallin, which has antioxidant and anti-inflammatory properties. Within the amla fruit, hydrolyzable tannins are the major bioactive components, with β-glucogallin being the most abundant hydrolyzable tannin.

The amla plant (Phyllanthus emblica L., also known as Emblica officinalis Gaertn.), popularly known as Indian gooseberry, is a small to medium-sized deciduous tree native to India and the Middle East, belonging to the family Euphorbiaceae. It grows in tropical and subtropical regions including Pakistan, Uzbekistan, Sri Lanka, South East Asia, China, and Malaysia.

3. Traditional and Historical Use

Beta-glucogallin itself has not historically been isolated or identified as a distinct substance in traditional medicine; rather, its traditional use is bound to that of its botanical sources — most prominently the amla fruit and oak-derived tannin preparations. The compound exists within these plants as an integral component of their bioactive phytochemical matrices.

3.1 Ayurvedic and Indian Traditional Medicine

Emblica officinalis, popularly known as Indian gooseberry or "Amla" in India, has been used in Ayurveda as a "rejuvenating herb" since ancient times. The plant Emblica officinalis has been used for thousands of years as a traditional Indian Ayurvedic preparation for the treatment of diabetes in humans.

As a key component of classic Ayurvedic formulations such as chyawanprash and triphala, amla (Phyllanthus emblica L.) is historically associated with improving immunity, digestion, and metabolism while nourishing the skin, hair, and cardiovascular tissues. It is commonly used in Ayurvedic medicine to treat respiratory infections, skin disorders, and gastrointestinal issues. The fruits of E. officinalis are widely used in Ayurveda and are believed to increase defense against diseases, with applications in cancer, diabetes, liver treatment, heart trouble, ulcer, anemia, and various other diseases.

Among the phytochemical constituents identified in amla, gallic acid and 1-O-galloyl-β-d-glucose (glucogallin) — along with 3,6-di-O-galloyl-d-glucose, 1,6-di-O-galloyl-β-d-glucose, chebulinic acid, and quercetin — are among the key components. Beta-glucogallin, as a major constituent of amla, was therefore consumed as part of these historical preparations, though without recognition as a discrete molecular entity.

Because beta-glucogallin exists within whole-plant preparations, the traditional therapeutic applications attributed to amla — including its uses as an antidiabetic, anti-inflammatory, rejuvenating, and hepatoprotective agent — reflect the activity of a matrix of compounds, of which beta-glucogallin is now understood to be a central pharmacologically active constituent.

4. Biosynthesis and Role in Plant Secondary Metabolism

Beta-glucogallin occupies a pivotal role in the plant biochemical pathway leading to the two major subclasses of hydrolyzable tannins: gallotannins and ellagitannins. The biosynthesis starts with the formation of β-glucogallin (1-O-galloyl-β-d-glucopyranose), which is generated by esterification of gallic acid and glucose and gives rise to di-, tri-, tetra-, and pentagalloylglucose by transesterification reactions.

Enzyme studies with extracts from oak leaves (Quercus robur) and from staghorn sumac (Rhus typhina) revealed that the pivotal intermediate 1,2,3,4,6-pentagalloylglucose is synthesized from β-glucogallin (1-O-galloyl-β-d-glucopyranose) by a series of strictly position-specific galloylation steps, affording so-called 'simple' gallotannins. Besides its role as starter molecule, β-glucogallin was also recognized as the principal energy-rich acyl donor required in these transformations.

On the basis of the structures and of the natural distribution of numerous galloylglucose esters, a metabolic pathway was postulated by Haslam and co-workers in 1982, comprising the sequence β-glucogallin → 1,6-digalloylglucose → 1,2,6-trigalloylglucose → tetragalloylglucose → 1,2,3,4,6-pentagalloylglucose.

In enzyme studies with sumac and oak, β-glucogallin (1-O-galloyl-β-d-glucose) is not only the first intermediate in this pathway but is also required as the principal activated acyl donor in the successive galloylation steps.

Although formation of β-glucogallin is the essential step in ellagitannin/gallotannin biosynthesis, only four genes coding for gallic acid UDP-glucose glucosyltransferases (GTs) had been isolated from Vitis vinifera and Quercus robur up to the time of recent reporting. The identification of further glycosyltransferases in the Rosaceae family (strawberry and raspberry) has substantially advanced understanding of how this gateway compound is formed across the plant kingdom.

All aromatic residues of galloylglucoses are directly or indirectly derived from β-glucogallin, meaning the entire class of hydrolyzable tannins constitutes a very homogeneous group of natural plant products that emerges from only one specific constituent surrounding the central polyol moiety.

5. Key Chemical Constituents and Mechanisms of Action

Beta-glucogallin, as a polyphenolic ester, is understood to exert its biological effects through multiple mechanistic pathways. The most rigorously studied of these are its inhibition of the enzyme aldose reductase, its free-radical scavenging activity, and its suppression of inflammatory signaling cascades.

5.1 Aldose Reductase (AKR1B1) Inhibition

BGG is a potent and selective inhibitor of the enzyme aldose reductase (AKR1B1), which is responsible for developing oxidative stress and secondary complications in diabetes. Aldose reductase (ALR2) is implicated in the development of secondary complications of diabetes including cataract and, therefore, has been a major drug target for the development of therapies to treat diabetic disease.

Bioassay-guided isolation and structure elucidation of 1-O-galloyl-β-d-glucose (β-glucogallin), identified as a major component from the fruit of the gooseberry, demonstrated selective as well as relatively potent inhibition (IC₅₀ = 17 µM) of AKR1B1 in vitro, with molecular modeling demonstrating that this inhibitor is able to favorably bind in the active site. Notably, inhibition studies demonstrated an IC₅₀ of approximately 17 µM against AKR1B1, and virtually no inhibition when assayed under similar conditions with the other major human AKR1 family members AKR1B10 (small intestine reductase) and AKR1A1 (aldehyde reductase), indicating a high degree of selectivity. This selectivity is considered pharmacologically important because non-selective ARI compounds have historically been associated with off-target effects.

Aldose reductase is an enzyme that contributes to cellular stress by production of reactive oxygen species (ROS) under high glucose conditions. By inhibiting this enzyme, beta-glucogallin reduces the polyol pathway flux that drives sorbitol and fructose accumulation in diabetic tissues.

5.2 Free-Radical Scavenging and Antioxidant Mechanisms

Owing to its free radical scavenging properties, β-glucogallin (BG) is believed to protect against several diseases like diabetes and related complications including retinopathy, glaucoma, inflammation, hepatic damage, and skin damage from UV. It has a significant photoprotective effect as it acts as a radical scavenger.

In macrophage studies, BGG pre-treatment showed a significant decrease in ROS, nitric oxide (NO), superoxide, and pro-inflammatory cytokines (TNF-alpha, IL-4, IL-17, IL-1β, and IL-6), and increased reduced glutathione coupled with the restoration of mitochondrial membrane potential.

5.3 Anti-Inflammatory Signaling Pathways

Gene profiling and further validation by qPCR showed that BGG pre-treatment downregulated the LPS-induced expression of c-Fos, Fas, MMP-9, iNOS, COX-2, MyD88, TRIF, TRAF6, TRAM, c-JUN, and NF-κB.

BGG pre-treatment reduced nuclear translocation of LPS-activated NF-κB and thus reduced the subsequent expressions of NLRP3 and IL-1β, indicating the ability of BGG to inhibit inflammasome formation. Molecular docking studies showed that BGG could bind at the active site of TLR4. The TLR4 receptor is the primary surface receptor through which gram-negative bacterial lipopolysaccharide (LPS) triggers inflammatory cascades; BGG's predicted binding at this site suggests a mechanism of action upstream of NF-κB activation.

In macrophage and ocular tissue studies, BGG prevents LPS-induced activation of JNK and p38 and oxidative stress, thus lowering ROS levels, indicating its potent anti-inflammatory activity. In RAW 267.4 macrophages, BGG attenuates the LPS-induced morphological changes and migration and inhibits activation of MMP-9.

5.4 Additional Reported Molecular Targets

Beta-glucogallin reduces ROS, PDGF (platelet-derived growth factor), RAGE (receptor for advanced glycation end products), and NF-κB, while it increases SOD (superoxide dismutase). The reduction in RAGE signaling is particularly relevant to the pathophysiology of advanced diabetic complications, where RAGE-mediated pathways contribute to vascular and neurological damage.

6. Scientific Evidence by Area of Use

6.1 Diabetic Complications: Cataract Prevention

The most thoroughly studied pharmacological application of beta-glucogallin is the inhibition of aldose reductase as a strategy to prevent or delay diabetic cataract formation. One major consequence of sorbitol formation via aldose reductase activity is that it can accumulate within lens cells, resulting in osmotic stress, which can lead to the breakdown of normal lens physiology and trigger cataract formation.

Key preclinical and ex vivo evidence: β-glucogallin effectively inhibits sorbitol accumulation by 73% at 30 µM under hyperglycemic conditions in an ex vivo organ culture model of lenses excised from transgenic mice overexpressing human ALR2 in the lens. Treatment of experimentally diabetic rats with crude extracts from amla fruit delayed the onset and progression of cataracts and prevented the accumulation of sorbitol and diabetes-induced markers of lipid peroxidation and protein oxidation products in the lens.

In a cell culture model using ARPE-19 (human retinal epithelial) cells, ARPE-19 cells exposed to methylglyoxal (MG) demonstrated an increase in oxidative stress with augmented (P<0.01) inflammatory cytokines such as COX-2, CXCR4, IL-6, IL-8, MCP-1, and ICAM-1 genes. Lens epithelial cells pre-treated with GG attenuated the reactive oxygen species levels with improved antioxidant enzymes, and the levels of aldose reductase and other inflammatory cytokines were observed at levels closer to control cells, suggesting that GG may be a potential drug for the prevention of cataract development and progression.

Evidence level: All currently published evidence on beta-glucogallin in cataract prevention is preclinical: in vitro cell culture studies, ex vivo lens organ cultures, and animal model experiments. No human clinical trials have been published to date. The animal and cell-based data are mechanistically consistent and pharmacologically meaningful, but translation to human clinical benefit has not been established.

6.2 Diabetic Retinopathy

Chronic hyperglycemia is an important risk factor involved in the onset and progression of diabetic retinopathy (DR), and aldose reductase (AR) has been linked to the pathogenesis of this degenerative disease. The purpose of one study was to investigate whether the novel AR inhibitor, beta-glucogallin (BGG), can offer protection against various hyperglycemia-induced abnormalities in human adult retinal pigment epithelial (ARPE-19) cells.

A marked decrease in cell viability (from 100% to 78%) following long-term exposure (4 days) of RPE cells to high glucose (HG) was largely prevented by siRNA-mediated knockdown of AR gene expression (from 79% to 97%) or inhibition using sorbinil (from 66% to 86%). In HG conditions, BGG decreased sorbitol accumulation (44%), ROS production (27%), as well as ER stress (22%).

BGG has low cytotoxicity and is capable of reducing ROS production and mitogen-activated protein kinase (MAPK) activation triggered by endotoxin.

Evidence level: Evidence is limited to in vitro human cell line studies. While the mechanistic rationale is sound — aldose reductase inhibition and antioxidant protection of retinal pigment epithelial cells — no clinical studies in humans with diabetic retinopathy have been conducted with isolated beta-glucogallin.

6.3 Glaucoma

Studies show that BGG provides a protective mechanism against oxidative stress-mediated glaucoma. Glaucoma causes permanent vision loss by damaging the optic nerve and retinal ganglion cells, increasing intraocular pressure, and involving toxic inflammatory factors that contribute to cell death and disease progression.

Cherry fruit (Muntingia calabura L.) contains β-glucogallin, which has antioxidant and anti-inflammatory properties; an in silico study investigated the potential of β-glucogallin in inhibiting the signaling pathway of TNFR1, matrix metalloproteinase 9 (MMP9), and endothelin receptor B (ETRB) linked to neurodegenerative illnesses in glaucoma.

Evidence level: Evidence on beta-glucogallin and glaucoma is at the in silico (computational molecular docking) stage. No in vivo or human clinical data are available for this specific application.

6.4 Inflammation and Sepsis

A published peer-reviewed study (International Journal of Molecular Sciences, 2022) evaluated beta-glucogallin's anti-inflammatory effects in both cellular and animal models. The anti-oxidant and anti-inflammatory effects of beta-glucogallin (BGG) were evaluated in both in vitro and in vivo studies, with the in vitro study investigating the ability of BGG pre-treatment to quench LPS-induced effects compared to LPS alone in macrophages.

The key in vitro findings included significant suppression of multiple inflammatory mediators. In the LPS-driven sepsis mouse model, pre-treatment with BGG sustained toxic shock, as evident from 100% survival, clearly showing the therapeutic potential of BGG in toxic shock syndrome.

Evidence level: In vitro (macrophage cell culture) and in vivo (mouse sepsis model) data only. Results are mechanistically compelling but cannot be extrapolated to human clinical outcomes without further trials.

6.5 Hepatoprotective Effects

Beta-glucogallin has antioxidant and hepatoprotective effects. A study investigating amelioration of carbon tetrachloride-induced hepatotoxicity by beta-glucogallin — a gallic acid derivative from Emblica officinalis — has been cited in the medicinal chemistry literature (Majeed et al., 2015, Science, 4(7): 696–701), though the available published literature on this topic remains limited to preclinical models.

Evidence level: Preliminary preclinical (animal toxicity model) data only. No human hepatoprotective studies with isolated beta-glucogallin have been published.

6.6 Antidiabetic Effects (Broader)

Beyond the polyol pathway, beta-glucogallin has been studied in the context of its parent plant extract's broader antidiabetic activity. A novel extract of E. officinalis fruit (Saberry®) containing 100 g kg⁻¹ beta-glucogallin along with hydrolyzable tannins was the subject of investigation for its antidiabetic potential, with the study aim being to investigate the antidiabetic and antioxidant activities of the fruit extract and its stability during gastric stress as well as its thermostability. This proprietary standardized extract formulation demonstrates the commercial and research interest in quantifying and delivering a specific beta-glucogallin content.

Evidence level: Some clinical-grade extract studies have evaluated beta-glucogallin-standardized preparations, but these have involved complex botanical mixtures rather than isolated beta-glucogallin. No controlled clinical trial isolating the contribution of beta-glucogallin alone to antidiabetic outcomes in humans has been published.

6.7 Photoprotection (UV-Induced Skin Damage)

Beta-glucogallin has a significant photoprotective effect as it acts as a radical scavenger. This property has been associated with protection against UV-induced oxidative damage to skin cells, linking it to the broader activity of polyphenolic antioxidants. Research into this application remains at the in vitro and theoretical stage; no clinical photoprotection trials using isolated beta-glucogallin have been reported.

7. Semisynthetic Derivatives and Drug Development

A significant challenge limiting beta-glucogallin's pharmaceutical development is the chemical lability of its ester linkage between gallic acid and glucose, which renders the native molecule susceptible to hydrolysis under acidic and thermal conditions. Through isosteric replacement of the ester for an amide linkage, researchers produced the novel derivative BGA, which proved to be stable under extreme heat and strong acid for an extended time course of 6 days.

Beta-glucogallin (BGG), a major component of the Emblica officinalis medicinal plant, is a potent and selective inhibitor of aldose reductase (AKR1B1). New linkages (ether/triazole/amide) were introduced via high-yielding, efficient syntheses to replace the labile ester, and an original two-step (90%) preparation of BGG was developed.

Inhibition of AKR1B1 was assessed in vitro and using transgenic lens organ cultures, which identified the amide-linked glucoside (BGA) as a stable, potent, and selective therapeutic lead toward the treatment of diabetic eye disease. Specifically, the IC₅₀ values of BGG and BGA were determined to be 8 ± 1 µM and 9 ± 2 µM, respectively, in the presence of the natural substrate glyceraldehyde, and both BGG and BGA showed no activity against AKR1B10 and AKR1A1, confirming maintained selectivity in the amide derivative.

Aldose reductase inhibitors (ARIs) developed to target AKR1B1 are generally non-selective and inhibit other members of the aldo-keto reductase superfamily, such as AKR1B10 and AKR1A1, which may contribute to toxicity and adverse effects. Despite the failure of ARIs such as sorbinil, zopalrestat, and tolrestat in clinical trials, the role of AKR1B1 in diabetic tissue damage has been thoroughly substantiated.

Several semisynthetic derivatives of β-glucogallin are being developed which have better pharmacokinetic and pharmacodynamic parameters than β-glucogallin itself. This active program of derivative design reflects an effort to improve upon the natural compound's pharmaceutical limitations while retaining its distinctive selectivity profile.

8. Commercial Forms and Preparations

In commercially available products, beta-glucogallin is most commonly encountered as a constituent of standardized amla (Emblica officinalis) extracts rather than as an isolated compound. Extracts of Emblica officinalis (amla) are produced from the fresh fruit and are standardized to their content of beta-glucogallin or tannins.

One such commercial preparation, trademarked as Saberry®, is specifically standardized to contain a defined beta-glucogallin content alongside other hydrolyzable tannins. A novel extract of E. officinalis fruit (amla fruit extract, AFE, Saberry®) containing 100 g kg⁻¹ (10%) beta-glucogallin along with hydrolyzable tannins has been investigated for antidiabetic potential.

In traditional and whole-food contexts, beta-glucogallin is naturally present in:

• Fresh amla fruit, which is the richest dietary source of amla's bioactive compounds, providing the full spectrum of tannins, flavonoids, gallic acid, ellagic acid, and beta-glucogallin.
• Chyawanprash — a traditional Ayurvedic jam-like preparation where amla is the primary ingredient, combined with ghee, honey, sesame oil, and numerous herbs and spices.
• Pomegranate, raspberry, mango, and Chinese white olive, all of which naturally contain beta-glucogallin as part of their hydrolyzable tannin fraction.

In laboratory and research settings, beta-glucogallin is also available as a purified reference compound for pharmacological investigation, but this form is designated for research use only and is not commercially marketed as a standalone dietary supplement.

9. Dosages Reported in Research

Because all published studies involving isolated beta-glucogallin have been conducted in preclinical (cell culture and animal) settings, the dosages reported reflect experimental concentrations rather than established human clinical doses.

• In vitro aldose reductase inhibition (IC₅₀): β-glucogallin displayed selective inhibition with an IC₅₀ = 17 µM of AKR1B1 in vitro.
• Ex vivo lens organ culture (sorbitol accumulation): β-glucogallin effectively inhibits sorbitol accumulation by 73% at 30 µM under hyperglycemic conditions in an ex vivo organ culture model.
• Cell culture (cataract study): Cells were pre-treated with GG (100 µM) for 2 hours prior to methylglyoxal (MG) treatment at 100 µM for 24 hours.
• In vitro AKR1B1 inhibition (amide derivative comparison): IC₅₀ values of BGG and BGA were 8 ± 1 µM and 9 ± 2 µM, respectively, using the natural substrate glyceraldehyde.
• Standardized extract (Saberry®): The extract contains 100 g kg⁻¹ (i.e., 10%) beta-glucogallin.

No established human therapeutic dose for isolated beta-glucogallin has been determined; all available dose data originate from in vitro or animal experiments.

10. Safety Considerations

Formal and comprehensive safety data for isolated beta-glucogallin in humans are not currently available in the peer-reviewed literature. However, several relevant observations from the research record are documented.

10.1 Cytotoxicity Profile

BGG has low cytotoxicity and is capable of reducing ROS production and mitogen-activated protein kinase (MAPK) activation triggered by endotoxin. This observation, from in vitro studies, suggests that at experimentally tested concentrations, the compound does not exhibit marked toxicity to human cell lines.

BGG is characterized as a non-cytotoxic, selective, and relatively potent AKR1B1 inhibitor that reduces sorbitol accumulation in vitro and in organ culture assays of transgenic mouse lenses.

10.2 Safety of the Source Plant (Emblica officinalis)

In vivo median lethal dose (LD₅₀) of a methanolic extract of Emblica officinalis fruit was determined to be 1125 mg/kg body weight in mice, suggesting a relatively wide safety margin for crude amla extracts in animal models. However, this refers to the whole extract and not isolated beta-glucogallin.

10.3 Pharmaceutical Stability

A key stability concern for beta-glucogallin as a pharmaceutical agent is the lability of its ester bond. Under acidic conditions (such as those encountered in the gastrointestinal tract) or elevated temperatures, the ester linkage is prone to hydrolysis. This motivated medicinal chemistry efforts: through isosteric replacement of the ester for an amide linkage, researchers overcame this instability, and the resulting derivative BGA proved to be stable under extreme heat and strong acid for an extended time course of 6 days. This inherent hydrolytic lability of the native beta-glucogallin molecule is relevant to its bioavailability and stability in formulated products.

10.4 Selectivity and Off-Target Safety

Unlike many previously developed synthetic aldose reductase inhibitors, beta-glucogallin demonstrates selectivity for AKR1B1 over closely related family members. Inhibition studies demonstrated an IC₅₀ of approximately 17 µM against AKR1B1, and virtually no inhibition when assayed under similar conditions with the other major human AKR1 family members AKR1B10 (small intestine reductase) and AKR1A1 (aldehyde reductase). This selectivity profile is considered favorable, as non-selective inhibition of related reductases has historically contributed to adverse effects in clinical trials of synthetic ARIs.

10.5 Drug Interaction Potential

No specific drug interaction studies for isolated beta-glucogallin in humans have been published. Given its potent inhibition of aldose reductase — an enzyme in the polyol pathway — and its suppression of NF-κB and inflammatory cytokines, theoretical interactions could exist with antidiabetic agents, anti-inflammatory drugs, or immunosuppressants, though no empirical interaction data are available. The broader literature on amla extract preparations notes their use alongside conventional diabetic therapies in traditional practice, but no controlled pharmacokinetic interaction studies specifically involving beta-glucogallin have been reported.

10.6 Research Status and Regulatory Standing

Beta-glucogallin as an isolated compound has not been formally evaluated by regulatory bodies such as the U.S. FDA, the European Food Safety Authority (EFSA), or the European Medicines Agency (EMA) as a standalone supplement or drug ingredient. It does not appear in WHO monographs, the European Pharmacopoeia, ESCOP monographs, or the German Commission E as an isolated entity. Its parent source plant, Phyllanthus emblica / Emblica officinalis, has been the subject of Ayurvedic monograph documentation, and amla-based extracts standardized to beta-glucogallin content are commercially marketed as dietary supplement ingredients in some jurisdictions. The compound itself remains primarily in the realm of preclinical research and pharmaceutical lead development.

11. Summary of Evidence Strength

• Aldose reductase inhibition (in vitro / ex vivo): Well-characterized mechanism with reproducible biochemical data; IC₅₀ values and selectivity established in multiple independent studies. No human clinical evidence.
• Diabetic cataract prevention: Consistent in vitro cell and ex vivo lens organ culture data; supported by diabetic rat model data using crude amla extract. No human trial data for isolated BGG.
• Diabetic retinopathy: Human retinal pigment epithelial cell line data available; mechanistically plausible via ARI activity and ROS suppression. No clinical trial data.
• Anti-inflammatory / sepsis: Compelling in vitro macrophage data and 100% murine survival in LPS-sepsis model; multiple inflammatory pathway targets identified. No human clinical evidence.
• Glaucoma: In silico (computational docking) data only. Highly preliminary.
• Hepatoprotection: Animal model data cited in literature; limited to one source with no peer-reviewed replication confirmed.
• UV photoprotection: Attributed to radical-scavenging properties; no dedicated human or animal in vivo studies with isolated BGG identified.

Across all areas, the current body of evidence for beta-glucogallin is preclinical. The compound has no confirmed human clinical trial evidence and should not be characterized as having established therapeutic benefit in any condition based on current published data.

References

• PubChem: Beta-Glucogallin (CID 124021) — National Library of Medicine / NIH
• Puppala M et al. (2012). The Isolation and Characterization of β-Glucogallin as a Novel Aldose Reductase Inhibitor from Emblica officinalis. PLoS ONE 7(4): e31399. PMC3317655
• Li L et al. (2014). Design of an Amide N-Glycoside Derivative of β-Glucogallin: A Stable, Potent, and Specific Inhibitor of Aldose Reductase. J Med Chem 57(1):71–77. PMC3956592
• Glucogallin Attenuates the LPS-Induced Signaling in Macrophages and Protects Mice against Sepsis. Int J Mol Sci. 2022;23(19):11254. PMC9569803
• Ma Y, Liu F, Xu Y (2019). Protective Effect of β-Glucogallin on Damaged Cataract Against Methylglyoxal Induced Oxidative Stress in Cultured Lens Epithelial Cells. Med Sci Monit 25:9310–9318. PMC6916131
• Schulenburg K et al. (2016). Formation of β-glucogallin, the precursor of ellagic acid in strawberry and raspberry. J Exp Bot 67(8):2299–2308. PMC4809288
• Chang KC et al. (2013). Beta-glucogallin reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of aldose reductase in murine macrophages and ocular tissues. Chem Biol Interact 202(1–3):283–287.
• Chang KC et al. (2014). Aldose reductase inhibition alleviates hyperglycemic effects on human retinal pigment epithelial cells. Chem Biol Interact 212:53–63.
• ScienceDirect Topics: Glucogallin — Overview of biosynthesis and enzymology.
• Niemetz R, Gross GG (2005). Enzymology of gallotannin and ellagitannin biosynthesis. Phytochemistry 66(17):2001–2011.
• Gross GG (1989). Biosynthesis of gallotannins: beta-glucogallin-dependent formation of 1,2,3,4,6-pentagalloylglucose. Arch Biochem Biophys 269(2):387–393. PubMed 2757399
• A Short Review on Glucogallin and its Pharmacological Activities. Mini-Rev Med Chem. 2022. Bentham Science Publishers.
• A Short Review on Glucogallin and its Pharmacological Activities. EurekaSelect / Bentham Science. 2022.
• Toxicological Evaluation of Emblica officinalis Fruit Extract and its Anti-inflammatory and Free Radical Scavenging Properties. PMC4745213
• Wikipedia: Glucogallin
• β-glucogallin from Muntingia calabura L. as glaucoma inhibitor: an in silico study. ResearchGate / 2024.
• Phyllanthus emblica: Phytochemistry, Antimicrobial Potential with Antibiotic Enhancement, and Toxicity Insights. PMC11945131
• Li L et al. (2014). Design of an Amide N-Glycoside Derivative of β-Glucogallin. J Med Chem 57(1):71–77. ACS Publications.